- $87.63m
- -$65.22m
- $16.58m
Seer Inc reports results for the quarter ended in September - Earnings Summary
Seer Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Seer Inc - Omead Ostadan Resigned As President And From Its Board Of Directors
Seer Inc reports results for the quarter ended in June - Earnings Summary
Brief: Seer Reports Q2 Revenue $3.6 Mln
Brief: Seer Q1 Revenue $3.3 Million
Seer Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Seer Announces Appointment Of Scott Thomas As Chief Commercial Officer
Seer Inc reports results for the quarter ended in December - Earnings Summary
Brief: Seer Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Full Year 2022 Outlook
Seer Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Seer Inc - President And Chief Operating Officer, Omead Ostadan, Was Returning From A Previously Announced 3 Month Leave Of Absence
Brief: Seer, Discovery Life Sciences And Sciex Announce Proteogenomics Consortium For Large-Scale Studies
Brief: Seer Inc Board Increased Authorized Size Of Board From Nine Directors To Ten Directors Effective November 29, 2021
Seer Inc reports results for the quarter ended in September - Earnings Summary
Brief: Seer Reports Third Quarter 2021 Financial Results
Seer Inc reports results for the quarter ended in June - Earnings Summary
Brief: Seer Reports Second Quarter 2021 Financial Results
Brief: Seer Bio Partners With Enlight Medical To Commercialize The Proteograph™ Product Suite In China